Skip to main content

Franklin Biotechnology Discovery Fund

Franklin Biotechnology Discovery Fund is an equity fund managed by Franklin Templeton in the Industri – Bioteknologi category.

About this fund

Franklin Biotechnology Discovery Fund is an equity fund run by Franklin Templeton, compared against the Industri – Bioteknologi peer group.

The fund: 26 years of track record, running since 2000 (share classes may be younger).

On return so far this year measured in NOK as of 16.11.2026, it places 3 of 4 funds in the group.

It is run by a team of 2.

The manager states a volatility of 20.7% for the fund.

The reference index is NASDAQ Biotechnology Index.

Manager
Franklin Templeton
Category
Industri – Bioteknologi
Region
Global
Sector
Information Technology
Style
Sector Focus
SFDR
Article 8
ISIN
LU0109394709
Inception
2000-04-03
Benchmark
NASDAQ Biotechnology Index
AUM
2.0 bn USD
Returns
YTD 4.0% · 1Y 12.5% · 3Y 22.9% · 5Y 13.2%

Portfolio managers

Actively managedEquityGlobalTechnology
YTD Return · NOK
+4,0 %from NAV
Calculated NOK return from USD · A (USD) (NOK Calculated)

Computed from NAV history (to 16 Nov 2026)

Last NAV 64,74 USD · 16 Nov 2026
Returns by period · NOK · net
ann. 3Y+
+4,0 %
YTD
+12,5 %
1y
+22,9 %
3y, annualised
+13,2 %
5y, annualised
+9,7 %
10y, annualised
Fund size
2,0 mrd. USD
Total fund AUM
Management fee
1,50 %
Annual · class A
Ongoing charge
1,81 %
Annual · class A
Annual cost on platforms
1,31 %–1,60 %
Class A · 5 platforms · net of platform rebate, incl. platform fee, excl. transaction costs
SFDR
Article 8
Sustainability
Launched
Apr 2000
ISIN LU0109394709
BenchmarkNasdaq Biotechnology
Fund website
Risk
Volatility (stated by the manager)20,7 %
Sharpe Ratio1,16
Max Drawdown18,8 %
About the fund
The fund

Franklin Biotechnology Discovery Fund has a track record back to 2000. The management company is Franklin Templeton, a listed US asset manager headquartered in San Mateo, California. The company gives 1947 as its founding year and has expanded through acquisitions, among them Legg Mason in 2020.

Investment philosophy

The mandate covers biotechnology companies and discovery research companies of any size. It includes companies in genomics, genetic engineering and gene therapy, and companies applying biotechnology in health care, pharmaceuticals and agriculture. The fund may invest worldwide, but may hold a large share in the US.

The managers

Evan McCulloch is lead manager and has managed the fund since 2000. He joined Franklin Templeton in 1992, led the healthcare team from 2000 to 2015 and was Director of Research for Franklin Equity Group from 2015 to 2023. Akiva Felt has been co-manager since 2020. He joined Franklin Templeton in 2018 from the hedge fund Asymmetry Capital and has covered biotechnology since 2007, most recently as a managing director on the sell side at Oppenheimer. Both are based in San Mateo and are part of Franklin Equity. McCulloch studied economics at Berkeley, while Felt has a background in biomedical engineering and biotechnology.

The portfolio

The portfolio is broad, with many companies spread from the smallest to the largest, and is almost fully invested in equities. Volatility has been slightly lower than that of comparable funds.

FundTelligence description · 18/10/2026
Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 share class outside the rule, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026

Portfolio managers

AK
Portfolio Manager
On the fund since Jan 31, 2020
EV
Portfolio Manager
On the fund since Nov 1, 2000

Position in the peer group

Industry Biotechnology Equities · 6 funds in the peer group. The number ranked and the date are stated per period. 3 of them converted to NOK.

2 of 4 funds ranked on a calculated return

#3/ 4Year to date
+3.96% NOK

as of 16 Nov 2026 · Converted from USD to NOK

About the figures

2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.

#3/ 41 year
+12.45% NOK

as of 16 Nov 2026 · Converted from USD to NOK

About the figures

2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.

#1/ 43 years (ann.)
+22.87% NOK

as of 16 Nov 2026 · Converted from USD to NOK

About the figures

2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.

#1/ 45 years (ann.)
+13.18% NOK

as of 16 Nov 2026 · Converted from USD to NOK

About the figures

2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.

Comparison basis

Year to date

Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 share class outside the rule, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026

1 year

Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 return as of an earlier date, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026

3 years (ann.)

Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 return as of an earlier date, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026

5 years (ann.)

Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 return as of an earlier date, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026

The positions describe historical return and are not an assessment of the fund, nor investment advice. Past performance is no guarantee of future returns. A position applies only within its own peer group and cannot be compared with positions in other peer groups.

Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.

About our data